Mr. William Hu is a Managing Partner of Qiming Venture Partners. William co-leads Qiming's investments in the healthcare sector.
William has been closely involved in the development of over 60 startup firms, some of which have become public companies or billion-dollar market cap companies. William has led investments in Tigermed (SZSE:300347, SEHK:3347), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), Tellgen (SZSE:300642), AmoyDx (SZSE:300685), Microtech Medical (SEHK:2235), Abbisko (SEHK:2256), Antengene (SEHK:6996), Rendu Biotechnology (SHSE:688193), CANbridge Pharmaceuticals (SEHK:1228), Aohua Endoscopy (SHSE:688212), Arrail Group (SEHK:6639), Connect Pharma (NASDAQ:CNTB), BBI Lifescience (SEHK:1035), Ark Bio, OriCell Therapeutics, SHIP Bio, Ribox Therapeutics, Vinno Medical, IntoCare Medtech, ET Healthcare, Health Genetech, WeDoctor, Yuanxin Technology, Medsci, Bang'Er Orthopedics Hospitals, ShuLan Hospital, etc.
William earned a Bachelor of Medicine degree from Shanghai Medical University and an MBA degree from ENPC SH Campus.
